cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.13130/rd_unimi/nsvbhr/mu8lrn
title: Giugno_1890_Pagina_087.jpg

description: Bulletin of 1890/06/22
DOI: 10.13130/rd_unimi/v8alup/gfkqym
title: Giugno_1891_Pagina_084.jpg

description: Bulletin of 1891/06/21
DOI: 10.25934/pr00012370
title: A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab (150 mg) With and Without a Subcutaneous Loading Regimen to Assess Efficacy, Safety, and Tolerability up to 2 Years in Patients With Active Ankylosing Spondylitis

description: The purpose of this study is to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and maintenance dosing using pre-filled syringe (PFS) and to assess efficacy, safety and tolerability up to 2 years in subjects with active AS despite current or previous NSAID, non-biologic DMARD, or biologic anti-TNFα therapy.
DOI: 10.25934/pr00012371
title: A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Study to Assess the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (Mini-Mental State Examination (MMSE) 10-20)

description: The purpose of this study is to assess the efficacy, safety, and tolerability of Exelon® patch in patients with probable AD (MMSE 10-20), in order to support a planned regulatory submission and registration of Exelon transdermal patch in China. The study is designed to confirm the non-inferiority of the efficacy of Exelon patch (target 10 cm² patch size) versus Exelon capsules (target 6.0 mg bid dose) on cognition, using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog).
DOI: 10.13130/rd_unimi/awv4gb/jiyry1
title: Giugno_1896_Pagina_040.jpg

description: Bulletin of 1896/06/10
DOI: 10.13130/rd_unimi/cbrkhv/yjs8b7
title: Gennaio_1927_Pagina_077.jpg

description: Bulletin of 1927/01/20
DOI: 10.13130/rd_unimi/xu1sm0/6fodpc
title: Giugno_1893_Pagina_062.jpg

description: Bulletin of 1893/06/16
DOI: 10.25934/pr00012372
title: A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes

description: This study was not conducted in the United States. The purpose of this study was to assess the safety and effectiveness of a number of doses of vildagliptin, an unapproved drug, in the treatment of people with type 2 diabetes.
DOI: 10.13130/rd_unimi/6np0bt/4l2dow
title: Giugno_1894_Pagina_046.jpg

description: Bulletin of 1894/06/12
DOI: 10.13130/rd_unimi/rjrjox/sz6iqo
title: Luglio_1895_Pagina_122.jpg

description: Bulletin of 1895/07/31
DOI: 10.25574/03215
title: Chandra X-ray Observatory ObsId 03215

description: EARLY-TYPE GALAXIES IN GROUPS: STRIPPING AND STIFLING
DOI: 10.25934/pr00012373
title: A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes

description: This study was not conducted in the United States. Many people with type 2 diabetes also have high cholesterol levels. The purpose of this study was to evaluate the effects of vildagliptin, an unapproved drug, on blood lipid measures such as triglycerides and cholesterol in people with type 2 diabetes.
DOI: 10.13130/rd_unimi/gsbgp1/xueltj
title: Giugno_1889_Pagina_103.jpg

description: Bulletin of 1889/06/26
DOI: 10.13130/rd_unimi/nsvbhr/wpymak
title: Giugno_1890_Pagina_088.jpg

description: Bulletin of 1890/06/22
DOI: 10.13130/rd_unimi/v8alup/4twy9h
title: Giugno_1891_Pagina_085.jpg

description: Bulletin of 1891/06/22
DOI: 10.25934/pr00012374
title: A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With Vildagliptin (50mg qd, 50mg Bid, 100mg qd) to Placebo in Patients With Type 2 Diabetes

description: This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 12-week clinical study is to evaluate the effect of vildagliptin 50mg qd, 50mg bid or 100mg qd compared to placebo in patients with type 2 diabetes.
DOI: 10.13130/rd_unimi/awv4gb/aluupk
title: Giugno_1896_Pagina_041.jpg

description: Bulletin of 1896/06/11
DOI: 10.13130/rd_unimi/cbrkhv/krg38y
title: Gennaio_1927_Pagina_078.jpg

description: Bulletin of 1927/01/20
DOI: 10.13130/rd_unimi/jvs9pt/qtqctg
title: Giugno_1892_Pagina_061.jpg

description: Bulletin of 1892/06/16
DOI: 10.25934/pr00012375
title: A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

description: The purpose of this study is to assess the safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar.
DOI: 10.13130/rd_unimi/6np0bt/xsim98
title: Giugno_1894_Pagina_047.jpg

description: Bulletin of 1894/06/12
DOI: 10.13130/rd_unimi/xu1sm0/5uqbaq
title: Giugno_1893_Pagina_063.jpg

description: Bulletin of 1893/06/16
DOI: 10.25574/03216
title: Chandra X-ray Observatory ObsId 03216

description: EARLY-TYPE GALAXIES IN GROUPS: STRIPPING AND STIFLING
DOI: 10.25934/pr00012376
title: A Multicenter, Double-Blind, Randomized, Parallel-Group Placebo-Controlled Study to Compare the Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Insulin.

description: The purpose of the study is to assess if the addition of vildagliptin as add-on therapy improves glucose variability in type 2 diabetes mellitus (T2DM) patients inadequately controlled with insulin, with special emphasis in hypoglycemic episodes measured by continuous glucose monitoring.
DOI: 10.13130/rd_unimi/gsbgp1/ryoqsb
title: Giugno_1889_Pagina_104.jpg

description: Bulletin of 1889/06/26
DOI: 10.13130/rd_unimi/nsvbhr/0v6y2a
title: Giugno_1890_Pagina_089.jpg

description: Bulletin of 1890/06/23
DOI: 10.13130/rd_unimi/rjrjox/ojp9rx
title: Luglio_1895_Pagina_123.jpg

description: Bulletin of 1895/07/31
DOI: 10.13130/rd_unimi/v8alup/bof3to
title: Giugno_1891_Pagina_086.jpg

description: Bulletin of 1891/06/22
DOI: 10.15468/dl.599g2b
title: Occurrence Download

description: A dataset containing 334 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is United States of America",
 "GadmGid is USA.20_1",
 "OccurrenceStatus is Present",
 "TaxonKey is Canis latrans"
 ]
}

 The dataset includes 334 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054866-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00012377
title: A Randomized, Single-blind, Placebo Controlled, Cross-over Study to Evaluate the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.

description: Please note this study is not being conducted in the United States. The purpose of this study is to assess the acute effects of vildagliptin, an unapproved drug, in reducing post-meal glucose levels by delaying gastric emptying.
DOI: 10.13130/rd_unimi/cbrkhv/kw35ne
title: Gennaio_1927_Pagina_079.jpg

description: Bulletin of 1927/01/20
DOI: 10.13130/rd_unimi/jvs9pt/ibomsd
title: Giugno_1892_Pagina_062.jpg

description: Bulletin of 1892/06/16
DOI: 10.25934/pr00012378
title: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia

description: This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL.
DOI: 10.25934/pr00012379
title: A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Active-controlled, Forced-titration, 12-week Comparison of Combined Angiotensin-neprilysin Inhibition With Sacubitril and Valsartan Versus Enalapril on Changes in Central Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)

description: To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection fraction \[LVEF\] ≤ 40%) after 12 weeks of treatment. The primary endpoint is the change in aortic characteristic impedance (Zc = dP/dQ in early systole) between baseline and Week 12.
DOI: 10.13130/rd_unimi/6np0bt/kynqjz
title: Giugno_1894_Pagina_048.jpg

description: Bulletin of 1894/06/12
DOI: 10.13130/rd_unimi/awv4gb/ddizt3
title: Giugno_1896_Pagina_042.jpg

description: Bulletin of 1896/06/11
DOI: 10.13130/rd_unimi/rjrjox/rvlddo
title: Maggio_1895_Pagina_015.jpg

description: Bulletin of 1895/05/04
DOI: 10.13130/rd_unimi/xu1sm0/altpfq
title: Giugno_1893_Pagina_064.jpg

description: Bulletin of 1893/06/16
DOI: 10.25574/03217
title: Chandra X-ray Observatory ObsId 03217

description: THE ASSEMBLY OF GALAXY GROUPS
DOI: 10.25934/pr00012380
title: A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)

description: The purpose of this study was to assess the effects of LIK066 on a variety of metabolic and inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)
DOI: 10.13130/rd_unimi/gsbgp1/4qo1gu
title: Giugno_1889_Pagina_105.jpg

description: Bulletin of 1889/06/27
DOI: 10.13130/rd_unimi/nsvbhr/8tv2ds
title: Giugno_1890_Pagina_090.jpg

description: Bulletin of 1890/06/23
DOI: 10.13130/rd_unimi/v8alup/icqz5g
title: Giugno_1891_Pagina_087.jpg

description: Bulletin of 1891/06/22
DOI: 10.25934/pr00012381
title: A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin

description: The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin without a history of, or current symptoms of carcinoid syndrome.
DOI: 10.13130/rd_unimi/cbrkhv/rhrwlv
title: Gennaio_1927_Pagina_080.jpg

description: Bulletin of 1927/01/20
DOI: 10.13130/rd_unimi/jvs9pt/nveupt
title: Giugno_1892_Pagina_063.jpg

description: Bulletin of 1892/06/16
DOI: 10.25934/pr00012382
title: RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

description: The purpose of this study was to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301 (NCT02375971)
DOI: 10.13130/rd_unimi/6np0bt/rjc7kt
title: Giugno_1894_Pagina_049.jpg

description: Bulletin of 1894/06/13
DOI: 10.13130/rd_unimi/awv4gb/w70pli
title: Giugno_1896_Pagina_043.jpg

description: Bulletin of 1896/06/11
DOI: 10.13130/rd_unimi/xu1sm0/nylqwe
title: Giugno_1893_Pagina_065.jpg

description: Bulletin of 1893/06/17
DOI: 10.25574/03218
title: Chandra X-ray Observatory ObsId 03218

description: FOSSIL GROUPS IN THE LOCAL UNIVERSE
DOI: 10.25934/pr00012383
title: Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Ejection Fraction (AWAKE-HF).

description: The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection fraction.
DOI: 10.13130/rd_unimi/gsbgp1/ewtoar
title: Giugno_1889_Pagina_106.jpg

description: Bulletin of 1889/06/27
DOI: 10.13130/rd_unimi/nsvbhr/bk55kr
title: Giugno_1890_Pagina_091.jpg

description: Bulletin of 1890/06/23
DOI: 10.13130/rd_unimi/rjrjox/sultc3
title: Maggio_1895_Pagina_017.jpg

description: Bulletin of 1895/05/05
DOI: 10.25934/pr00012384
title: A Multi-center, Prospective, Randomized, Double-blind Study to Assess the Impact of Sacubitril/Valsartan vs. Enalapril on Daily Physical Activity Using a Wrist Worn Actigraphy Device in Adult Chronic Heart Failure Patients

description: The purpose of this randomized, actively controlled, double-blind study with prospective data collection was to assess differences between sacubitril/valsartan versus enalapril in increasing exercise capacity and non-sedentary physical activity in HFrEF patients. Physical activity was assessed by the 6 minute walk test, and daily physical activity was continuously measured by means of a wrist-worn accelerometry device from 2 weeks before until 12 weeks after start of study therapy (sacubitril/valsartan or enalapril).
DOI: 10.13130/rd_unimi/cbrkhv/oufyra
title: Gennaio_1927_Pagina_081.jpg

description: Bulletin of 1927/01/21
DOI: 10.13130/rd_unimi/jvs9pt/q00pnq
title: Giugno_1892_Pagina_064.jpg

description: Bulletin of 1892/06/16
DOI: 10.13130/rd_unimi/v8alup/erlppf
title: Giugno_1891_Pagina_088.jpg

description: Bulletin of 1891/06/22
DOI: 10.25934/pr00012385
title: A 24-week Multi-center, Double-blind, Placebo Controlled Dose-range Finding Study to Investigate the Efficacy and Safety of Oral QBW251 in COPD Patients on Triple Inhaled Therapy (LABA / LAMA / ICS)

description: This clinical study was designed to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in Chronic obstructive pulmonary disease (COPD) patients with chronic bronchitis and a history of exacerbations, compared to placebo, when added to a triple inhaled therapy of LABA, LAMA and ICS.
DOI: 10.13130/rd_unimi/6np0bt/ieg2ge
title: Giugno_1894_Pagina_050.jpg

description: Bulletin of 1894/06/13
DOI: 10.13130/rd_unimi/awv4gb/uivixh
title: Giugno_1896_Pagina_044.jpg

description: Bulletin of 1896/06/11
DOI: 10.13130/rd_unimi/xu1sm0/sjhplp
title: Giugno_1893_Pagina_066.jpg

description: Bulletin of 1893/06/17
DOI: 10.25574/03219
title: Chandra X-ray Observatory ObsId 03219

description: GALAXY WAKES: THE FIRST SAMPLES
DOI: 10.25934/pr00012386
title: A Randomized, Investigator-Blinded, Multicenter, Parallel-Group Study to Compare Efficacy, Safety and Tolerability of Arthemeter/ Lumefantrine Dispersible Tablet Formulation vs. Artemether/ Lumefantrine 6-Dose Crushed Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants and Children.

description: This study will evaluate the safety and efficacy of artemether-lumefantrine against uncomplicated malaria caused P. falciparum in children of 5-35 kg bodyweight.
DOI: 10.13130/rd_unimi/gsbgp1/dppiqv
title: Giugno_1889_Pagina_107.jpg

description: Bulletin of 1889/06/27
DOI: 10.13130/rd_unimi/nsvbhr/aiuhak
title: Giugno_1890_Pagina_092.jpg

description: Bulletin of 1890/06/23
DOI: 10.13130/rd_unimi/rjrjox/67ngf1
title: Maggio_1895_Pagina_018.jpg

description: Bulletin of 1895/05/05
DOI: 10.25934/pr00012387
title: Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)

description: This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years with COVID-19 disease.
DOI: 10.13130/rd_unimi/cbrkhv/yjesig
title: Gennaio_1927_Pagina_082.jpg

description: Bulletin of 1927/01/21
DOI: 10.13130/rd_unimi/jvs9pt/ballzm
title: Giugno_1892_Pagina_065.jpg

description: Bulletin of 1892/06/17
DOI: 10.13130/rd_unimi/v8alup/zfiw03
title: Giugno_1891_Pagina_089.jpg

description: Bulletin of 1891/06/23
DOI: 10.25934/pr00012388
title: A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

description: This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s). The study will be a multicenter study in the United States.
DOI: 10.13130/rd_unimi/6np0bt/dcc5dc
title: Giugno_1894_Pagina_051.jpg

description: Bulletin of 1894/06/13
DOI: 10.13130/rd_unimi/awv4gb/48rcmv
title: Giugno_1896_Pagina_045.jpg

description: Bulletin of 1896/06/12
DOI: 10.13130/rd_unimi/xu1sm0/8ctb5v
title: Giugno_1893_Pagina_067.jpg

description: Bulletin of 1893/06/17
DOI: 10.25574/03220
title: Chandra X-ray Observatory ObsId 03220

description: THE PUZZLING DUMB-BELL GALAXY NDC 4782/3: GALACTIC WAKES VERSUS BENT JETS
DOI: 10.25934/pr00012389
title: A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) or ACSVD Risk-Equivalents and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

description: This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s). The study will be an international multicenter study (non-United States).
DOI: 10.25934/pr00012390
title: A Multiple-dose, Subject and Investigator Blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885(Canakinumab) in Patients With Pulmonary Sarcoidosis

description: The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.
DOI: 10.13130/rd_unimi/gsbgp1/slfbwk
title: Giugno_1889_Pagina_108.jpg

description: Bulletin of 1889/06/27
DOI: 10.13130/rd_unimi/nsvbhr/qk5vx3
title: Giugno_1890_Pagina_093.jpg

description: Bulletin of 1890/06/24
DOI: 10.25934/pr00012391
title: A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE).

description: The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study also assessed the safety and tolerability of secukinumab.
DOI: 10.13130/rd_unimi/jvs9pt/5gzmyc
title: Giugno_1892_Pagina_066.jpg

description: Bulletin of 1892/06/17
DOI: 10.13130/rd_unimi/rjrjox/1cocny
title: Maggio_1895_Pagina_019.jpg

description: Bulletin of 1895/05/05
DOI: 10.13130/rd_unimi/v8alup/fad1tg
title: Giugno_1891_Pagina_090.jpg

description: Bulletin of 1891/06/23
DOI: 10.25934/pr00012392
title: A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE)

description: The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study assessed the safety and tolerability of secukinumab.
DOI: 10.13130/rd_unimi/6np0bt/9crck1
title: Giugno_1894_Pagina_052.jpg

description: Bulletin of 1894/06/13
DOI: 10.13130/rd_unimi/cbrkhv/lv3mta
title: Gennaio_1927_Pagina_083.jpg

description: Bulletin of 1927/01/21
DOI: 10.13130/rd_unimi/xu1sm0/kspoyo
title: Giugno_1893_Pagina_068.jpg

description: Bulletin of 1893/06/17
DOI: 10.25574/03221
title: Chandra X-ray Observatory ObsId 03221

description: CHANDRA OBSERVATIONS OF A Z=0.84 GALAXY CLUSTER AND ITS CENTRAL HST QSO
DOI: 10.25934/pr00012393
title: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Psoriatic Arthritis

description: The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3 mg/kg administered every four weeks) in patients with active psoriatic arthritis (PsA) despite current or previous Non-steroidal anti-inflammatory drugs (NSAIDs), Disease-modifying antirheumatic drugs (DMARDs) and/or anti-tumor necrosis factor (TNF) therapy.
DOI: 10.13130/rd_unimi/awv4gb/dm3whb
title: Giugno_1896_Pagina_046.jpg

description: Bulletin of 1896/06/12
DOI: 10.13130/rd_unimi/gsbgp1/dhmxei
title: Giugno_1889_Pagina_109.jpg

description: Bulletin of 1889/06/28
DOI: 10.13130/rd_unimi/nsvbhr/k9gypv
title: Giugno_1890_Pagina_094.jpg

description: Bulletin of 1890/06/24
DOI: 10.25934/pr00012394
title: Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS)

description: The purpose of this study was to determine the dose-response relationship of VAY736 for key efficacy and safety parameters
DOI: 10.13130/rd_unimi/jvs9pt/hwmvfw
title: Giugno_1892_Pagina_067.jpg

description: Bulletin of 1892/06/17
DOI: 10.13130/rd_unimi/v8alup/x1ehy4
title: Giugno_1891_Pagina_091.jpg

description: Bulletin of 1891/06/23
DOI: 10.25934/pr00012395
title: A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis

description: The purpose of the CSEG101A2202 study was to characterize the Pharmacokinetic (PK) and Pharmacodynamic (PD) of SEG101/crizanlizumab and to evaluate the safety and efficacy of SEG101/crizanlizumab in sickle cell disease (SCD) patients.
DOI: 10.13130/rd_unimi/cbrkhv/hpuo9l
title: Gennaio_1927_Pagina_084.jpg

description: Bulletin of 1927/01/21
DOI: 10.13130/rd_unimi/rjrjox/q3hhwm
title: Maggio_1895_Pagina_007.jpg

description: Bulletin of 1895/05/02
DOI: 10.13130/rd_unimi/xu1sm0/d2xqtc
title: Giugno_1893_Pagina_069.jpg

description: Bulletin of 1893/06/18
DOI: 10.25574/03222
title: Chandra X-ray Observatory ObsId 03222

description: THE ORIGIN OF X-RAY EMISSION FROM LOW VELOCITY DISPERSION GROUPS
DOI: 10.25934/pr00012396
title: A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment

description: The main aim of this study was to evaluate the efficacy and safety of adding ribociclib to fulvestrant in men and postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced breast cancer.
DOI: 10.13130/rd_unimi/6np0bt/iaoslq
title: Giugno_1894_Pagina_053.jpg

description: Bulletin of 1894/06/14
DOI: 10.13130/rd_unimi/awv4gb/fkppnv
title: Giugno_1896_Pagina_047.jpg

description: Bulletin of 1896/06/12